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Objectives: A routine review of hepatitis A travel vaccination recommendations was brought
forward in June 2017 due to hepatitis A vaccine shortages and a concurrent outbreak in
men who have sex with men (MSM). There were three objectives: first, to document the
review process for changing the recommendations for the UK travellers in June 2017.
Second, to study the impact of these changes on prescribing in general practice in 2017
compared with the previous 5 years. Third, to study any changes in hepatitis A notifica-
tions in JuneeOctober 2017 compared with the previous 5 years.
Study design: This is an observational study.
Methods: Travel vaccination recommendations for countries with either low-risk (<20%) or
high-risk (>90%) status according to child hepatitis A seroprevalence were not changed. A
total of 67 intermediate-risk countries with existing recommendations for most travellers
and with new data on rural sanitation levels were shortlisted for the analysis. Data on child
hepatitis A seroprevalence, country income status, access to sanitation in rural areas and
traveller volumes were obtained. Information about the vaccine supply was obtained from
Public Health England. Changes to the existing classification were made through expert
consensus, based on countries' hepatitis A seroprevalence, sanitation levels, level of in-
come, volume of travel and hepatitis A traveller cases. Data on the number of combined
and monovalent hepatitis Aecontaining vaccines prescribed in England, 2012e2017, were
obtained from the National Health Service Business Service Authorities. The number of
monthly prescriptions for JanuaryeSeptember 2017 was compared with the mean number
of prescriptions for the same month in the previous 5 years (t-test, a ¼ 5%, df ¼ 4). Theuk (J. Petersen).
ic Health. Published by Elsevier Ltd. All rights reserved.
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was compared with the number of notifications in the same months in previous years.
Results: A total of 36 countries were downgraded based on good access (80þ% of population)
to sanitation in rural areas and the intermediate-risk status in terms of child hepatitis A
seroprevalence. For these countries, vaccination would only be recommended to travellers
staying long term, visiting friends and relatives or staying in areas without good sanitation.
There was a significant decline in hepatitis A vaccine prescriptions in JuneeSeptember
2017, and there was no increase in the number of notifications.
Conclusions: Hepatitis A vaccination recommendations for travel were revised in 2017
following a systematic approach to maintain continuity of supply after a hepatitis A vac-
cine shortage and increased hepatitis A vaccine demand related to a large outbreak.
Improved access to good sanitation in rural areas and low seroprevalence estimates among
children have led to 36 countries to no longer require vaccination for most travellers. These
changes do not seem to have impacted on hepatitis A notifications in England, although
further research will be needed to quantify the impact more precisely.
© 2018 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved., et al., Changes to count
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Hepatitis A is transmitted faeco-orally via contaminated food
and drink, direct contact or sexual activity.1 It typically leads
to mild liver disease but in rare cases, can lead to fulminant
hepatitis and death. There is no specific treatment for hepa-
titis A, and recovery can take weeks and months.1 Globally,
theWorld Health Organization (WHO) estimates that there are
more than 120 million cases per year.2 Most cases in England
and Wales are travel associated, and nearly 250 cases in
returning travellers were diagnosed in England and Wales in
2014.3
Hepatitis A vaccines are safe and effective. The duration of
protection from a completed two-dose course of vaccine can
be expected to be at least 25 years in immunocompetent in-
dividuals. After this primary course, a booster dose is recom-
mended at 25 years for those at ongoing risk.1,4
An outbreak of hepatitis A among men who have sex with
men (MSM) affecting England since July 2016 and other parts
of the world5 exacerbated an ongoing global shortage of hep-
atitis A vaccine. As the UK vaccine supply was severely
impacted in Spring 2017, Public Health England (PHE) took a
multipronged approach to mitigate supply constraints and
respond to the outbreak in MSM. In June 2017, PHE, with the
endorsement of the Joint Committee on Vaccination and
Immunisation, issued temporary hepatitis A vaccine recom-
mendations on risk-based prioritisation of patients, dose-
sparing and alternative vaccine use to preserve the stock for
those most likely to benefit from the vaccine.6 A planned re-
view of country-specific travel vaccination recommendations
was brought forward and implemented alongside PHE's tem-
porary vaccine recommendations. Hepatitis A vaccine was
prioritised and offered opportunistically to all MSM attending
sexual health services.7
This article describes the review approach and process for
revising the country-specific travel vaccinations and exam-
ines evidence of the impact on prescribing in general practice
during 2017 versus the previous 5 years and on the number of
notified cases of hepatitis A before and during 2017.Methods
The existing country-specific hepatitis A vaccination recom-
mendations for UK travellers before June 2017 were based on
the WHO data on child hepatitis A virus seroprevalence,8
country income status (high-income status versus any lower
status)9 and access to sanitation in rural areas (90þ% of
population).10
Travel vaccination recommendations for countries with
either low-risk (<20%) or high-risk (>90%) status according to
child hepatitis A seroprevalence were not changed. Vaccina-
tion continues to be recommended for ‘most’ travellers to
high-risk countries, whereas vaccination is not recommended
for travellers to low-risk countries.
As a cautious approach, vaccination was recommended for
‘most’ travellers to intermediate-risk countries in the existing
recommendations, except for the countries with high-income
status and where 90þ% of the rural population had access to
good sanitation. For these countries, vaccination would only
be recommended for ‘some’ travellers.
The terminology, ‘most’ versus ‘some’ travellers, is
routinely used for travel vaccination advice in the UK. For
countries with a ‘most’ recommendation, vaccine is recom-
mended for all travellers, unless there is a specific reason not
to. Several factors will determine whether travellers visiting
countries with a ‘some’ recommendation should be vacci-
nated; these include the following: individual health status,
duration and purpose of travel and planned activities associ-
ated with higher risk. In the case of hepatitis A, vaccination is
recommended for those planning a long-term stay, visiting
friends and relatives or visiting areas with poor sanitation.
For the updated classification, the analyses included the
most recent WHO and the United Nations International Chil-
dren's Emergency Fund data on rural sanitation levels.11 At the
time of the review, no new comprehensive data set was
available on child seroprevalence.
The review of the country-specific recommendation was
carried out in two stages. First, a modification of the existing
criteria was considered, such as lowering the threshold forry-specific hepatitis A travel vaccination recommendation for UK
ational context, Public Health (2018), https://doi.org/10.1016/ibrary from ClinicalKey.com by Elsevier on November 21, 2018.
. Copyright ©2018. Elsevier Inc. All rights reserved.
p u b l i c h e a l t h x x x ( 2 0 1 8 ) 1e7 3access to sanitation in rural areas from 90% to either 80% or
70% and removing the existing high-income country criterion.
The previous review incorporated the World Bank income
status. The income status is correlated with access to good
sanitation and therefore, not strictly needed in this particular
construct. Incorporating the income status at the same time
meant that a number of countries with significant improve-
ment in access to good sanitation would unnecessarily be
excluded from consideration in the full review process. Sec-
ond, the results were discussed by an expert panel taking
additional factors into account such as available data on
foreign travel-associated hepatitis A cases, volumes and pur-
pose of travel.
The total number of intermediate-risk countries under
review was 67; of these, 25 had figures for the proportion of
rural population with access to good sanitation between 90%
and 100%, 15 between 80% and 89% and eight between 70%
and 79%. The remaining countries had figures below 70%. Data
on the volume of travel to specific destinations were obtained
from the International Passenger Survey on visits abroad un-
dertaken by residents in England, 2013e2016, and averaged
over the 4 years.12
Information about vaccine supply issues was obtained
from PHE's Vaccine Update newsletters, MarcheSeptember
2017.13 The shortage was first mentioned in March 2017.
Data on the number of hepatitis Aecontaining vaccines
(monovalent hepatitis A, combined hepatitis A/hepatitis B and
hepatitis A/typhoid) prescribed in general practice in England
between January 2012 and September 2017 were obtained
from the National Health Service (NHS) Business Service Au-
thorities.14 The number of monthly prescriptions between
January and September 2017 was compared with the mean
number of prescriptions for the same month in the previous
5 years as a reference period with no known incidences of
vaccine shortage using t-tests (single versus multiple obser-
vation two-group equivalence of means, a ¼ 5%, df ¼ 4).15
To estimate the combined impact of the revised recom-
mendations and vaccine supply issues on disease incidence,
we compared the number of hepatitis A cases (excluding cases
associated with the MSM outbreak) notified to PHE between
June and October 2017, with the number of notifications in the
same time period in the previous 4 years (excluding those
associated with the MSM outbreak in 2016), using a test for
trends. These cases are not exclusively travel associated, but
asmost cases in England are travel related, these numbers can
be used as a crude way to evaluate whether the aforemen-
tioned factors have had a major impact on disease
notifications.Results
Review of country recommendations review
A total of 67 intermediate-risk countries with existing recom-
mendations for most travellers and with new data on rural
sanitation levels were shortlisted for the analysis. Jamaica had
previously been assigned to the lower risk, ‘some’ travellers
status based on the expert consensus, but was included in the
analysis for a comparisonof the effectofdifferent criteria (TablePlease cite this article in press as: Petersen J, et al., Changes to countr
travellers in 2017dresponding to a vaccine shortage in the n
j.puhe.2018.09.017
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90þ% threshold for rural sanitation, would ‘release’ 25 lower
income countries with good rural sanitation for consideration
in a downgrading exercise. Lowering the rural sanitation
threshold from 90þ% to 80þ% would include a further 15
countries. Lowering the threshold still further from 80þ% to
70þ% would only increase the list of countries with another
eight countries. Based on the expert consensus taking into ac-
count the number of travel-associated cases of hepatitis A
against the traveller flows and types of traveller to those
countries, and any other factors (such as the rates of other
gastro-intestinal illness), Egypt, Syria and Tunisia were reas-
signed to the stricter ‘most’ travellers category. In some in-
stances, the political stability and infrastructure of a country
were taken into consideration. Therefore, the total number of
countries that were downgraded from ‘most’ to ‘some’ as a
result of this exercisewas 36 (Table 1; as indicated in columnK).
Hepatitis A vaccine prescribing
Compared with themean number of prescriptions of hepatitis
Aecontaining vaccines for the same month in the previous 5
years, prescription numbers dropped by 23% in June 2017, 33%
in July, 47% in August and 56% in September (P < 0.05 for all,
Fig. 1). Hepatitis A/hepatitis B vaccine prescriptions were also
significantly lower in February and April of 2017 compared
with those months in the previous 5 years (24% and 33%,
respectively).
There were no or only limited supply of most adult vac-
cines from manufacturers during MarcheSeptember 2017
(end of the study period), although supply constraints for
hepatitis A/hepatitis B combination vaccine were only re-
ported from July 2017 onwards (Table 2). The vaccine shortage
was less severe for child/adolescent vaccines early in the year,
but only limited stock was available from July onwards. There
was a limited supply of one of the hepatitis A typhoid vaccine
products in March and April for both adults and adolescents,
after which there were no supply of either product for the rest
of the study period.
The number of visits abroad to countries where 'most'
travellers would be recommended hepatitis A vaccination
(assuming that they either had not been vaccinated previously
or a booster was due) is estimated, as a result of the revised
recommendations, to have fallen from 7.4 million (2013e2016
average) to 2.5 million visits (2017) per year, i.e. a 66%
decrease.
Hepatitis A notifications
Between June and October 2017, 244 hepatitis cases were
notified to PHE, excluding those associated with the MSM
outbreak, compared with an average of 230 in 2013e2016
(Table 3). No trend in notification was detected between 2013
and 2017 (P ¼ 0.17).Discussion
JuneeJuly are the peak months for hepatitis A vaccination in
the lead up the main UK holiday period in August. In 2017,y-specific hepatitis A travel vaccination recommendation for UK
ational context, Public Health (2018), https://doi.org/10.1016/rary from ClinicalKey.com by Elsevier on November 21, 2018.
Copyright ©2018. Elsevier Inc. All rights reserved.
Table 1 e Hepatitis A country classification revisiteddwith and without high-income status, latest rural sanitation data and variable sanitation threshold.
Country Travellers
per year
2013e2016
VFR% Economic
status
Sanitation% Rural
(previous review)
Sanitation%
Rural (new)
2015 Review
decision
Predicted based
on high-income
and 90þ% rural
sanitation (previous)
Predicted based
on 90þ% rural
sanitation (new)
Predicted based
on 80þ% rural
sanitation (new)
Predicted based
on 70þ% rural
sanitation (new)
A B C D E F G I J K L
Albania 35,423 54.2 Low 86 90 Most Most Some Some Some
Argentina 25,607 28.9 Low 99 98 Most Most Some Some Some
Belarus 8563 52.4 Low 95 95 Most Most Some Some Some
Bosnia and Hz. 10,624 47.3 Low 92 92 Most Most Some Some Some
Chile 12,143 22.3 High 89 91 Most Most Some Some Some
Egypta 248,480 14.9 Low 94 93 Most Most Some Some Some
Jordan 28,327 37.8 Low 98 99 Most Most Some Some Some
Kazakhstan 11,284 35.9 Low 98 98 Most Most Some Some Some
Kyrgyzstan 2628 40.9 Low 92 96 Most Most Some Some Some
Libya 16,278 48.2 Low 96 96 Most Most Some Some Some
Malaysia 102,963 39.8 Low 95 96 Most Most Some Some Some
The Maldives 48,799 1.1 Low 100 98 Most Most Some Some Some
Mauritius 114,408 16.5 Low 90 93 Most Most Some Some Some
Montenegro 25,330 11.3 Low 87 92 Most Most Some Some Some
Palau e e Low 100 100 Most Most Some Some Some
Samoa e e Low 91 91 Most Most Some Some Some
Serbia 47,014 61.0 Low 96 94 Most Most Some Some Some
Sri Lanka 112,580 41.5 Low 94 97 Most Most Some Some Some
Syriaa 810 100 Low 95 95 Most Most Some Some Some
Tajikistan 1204 0 Low 95 95 Most Most Some Some Some
Thailand 372,618 18.0 Low 96 96 Most Most Some Some Some
Ukraine 48,176 50.3 Low 89 93 Most Most Some Some Some
Uzbekistan 5154 33.1 Low 100 100 Most Most Some Some Some
Poland 1,729,136 70.7 High 97 Most Some Some Some
Reunion e e 95 Most Some Some Some
Algeria 55,106 77.0 Low 88 82 Most Most Most Some Some
Azerbaijan 7997 32.0 Low 78 87 Most Most Most Some Some
Belize 2044 14.5 Low 88 88 Most Most Most Some Some
Bulgaria 289,211 33.3 Low 100 84 Most Most Most Some Some
Cuba 134,466 3.4 Low 88 89 Most Most Most Some Some
Fiji 2371 40.7 Low 82 88 Most Most Most Some Some
Guyana 2607 0 Low 82 82 Most Most Most Some Some
Iran 48,330 80.2 Low 82 82 Most Most Most Some Some
Iraq 41,403 63.8 Low 82 84 Most Most Most Some Some
Jamaicab 190,532 35.8 Low 82 84 Some Most Most Some Some
Lithuania 238,799 77.2 High 85 83 Most Most Most Some Some
Tonga e e Low 89 89 Most Most Most Some Some
Tunisiaa 253,878 5.9 Low 77 80 Most Most Most Some Some
Turkey 1,172,756 6.0 Low 75 86 Most Most Most Some Some
Latvia 152,340 68.6 High 82 Most Most Some Some
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Fig. 1 e Prescribing of HAV-containing vaccines in 2017
versus monthly averages from 2012 to 2016. Observations
significantly different from the 2012e2016mean at 5% level
marked with * (t-test, df¼ 4). The vertical line indicates the
month where changes to country-specific travel
vaccination and dose-sparing recommendations were
implemented. HAV, hepatitis A; HBV, hepatitis B.
p u b l i c h e a l t h x x x ( 2 0 1 8 ) 1e7 5
Please cite this article in press as: Petersen J, et al., Changes to countr
travellers in 2017dresponding to a vaccine shortage in the n
j.puhe.2018.09.017
Downloaded for Anonymous User (n/a) at Bloomsbury Healthcare Lib
For personal use only. No other uses without permission. however, there was a decrease of 23% in vaccinations in June,
the month of the change in recommendations, and of 33%,
47% and 56% in July, August and September, respectively. The
fact that the total number of hepatitis A and hepatitis A
combination vaccine prescriptions had already begun to
decrease in June suggests that the vaccine supply constraints
also played a role in the overall decline as ordering restrictions
were imposed by manufacturers. The estimated decline in
vaccinations required for ‘most’ travellers was 66% assuming
the prior unvaccinated status. These data are consistent with
the observed decrease in vaccine prescriptions. Limited data
on hepatitis A notifications suggest that the changes in rec-
ommendations, taken together with the concurrent vaccine
supply issues, have not led to a large increase in hepatitis A
importation to England. The supply situation is expected to
improve in 2018, and only a longer time series will be able to
reveal the overall impact on disease incidence, if any, of the
changes to the country-specific recommendations.
Limitations
Data on hepatitis A vaccinationswere only available fromNHS
general practice (GP), where the vaccine can be obtained for
free both in response to outbreaks and for overseas travel.16 In
practice, hepatitis A travel vaccinations are also administered
in private travel clinics and private GP practices. There is no
centralised database for private travel clinics and private
prescriptions.17 Hypothetically, some of the bigger, private
chains of travel clinics may be more resilient to shortages
comparedwith the smaller GP practices as the stock is likely to
be purchased centrally in bulk and distributed within the
organisation. So, even though the vaccine is available for free
in general practice (NHS), it is possible that some travellers
will have been able to obtain vaccination in the private sector
during the shortage. The analysis of hepatitis A notifications is
limited as it is not possible to differentiate travel-associatedy-specific hepatitis A travel vaccination recommendation for UK
ational context, Public Health (2018), https://doi.org/10.1016/rary from ClinicalKey.com by Elsevier on November 21, 2018.
Copyright ©2018. Elsevier Inc. All rights reserved.
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Table 3 e Hepatitis A notifications, 2013e2016.a
Time period Notifications
JuneeOctober 2013 159
JuneeOctober 2014 232
JuneeOctober 2015 276
JuneeOctober 2016 251
JuneeOctober 2017 244
MSM, men who have sex with men.
a Excludes cases associated with the MSM outbreak ongoing since
July 2016.
p u b l i c h e a l t h x x x ( 2 0 1 8 ) 1e76
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For personal use only. No other uses without permissioncases from others in the current data. While most cases in
England are travel associated, the data provide reassurance
that the travel hepatitis A vaccination changes have not led to
a large increase in hepatitis A incidence. Restricting the
analysis to travel-associated cases, including the country of
travel will enable a more precise estimation of the impact of
the changes on recommendations. There is often a lag of
several months in these data becoming available.
Conclusions
Hepatitis A vaccination recommendations for travel were
revised in 2017 following a systematic approach to maintain
continuity of supply after a hepatitis A vaccine shortage and
increased hepatitis A vaccine demand related to a large
outbreak. Improved access to good sanitation in rural areas
and low seroprevalence estimates among children have led to
36 countries to no longer require vaccination for most trav-
ellers. These changes do not seem to have impacted on hep-
atitis A notifications in England, although further researchwill
be needed to quantify the impact more precisely.Author statements
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